CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?

BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the E...

Descripción completa

Detalles Bibliográficos
Autores principales: PINTO, Thiago David Alves, ALVES, Thaís David das Neves, PINTO, Sebastião Alves, OLIVEIRA, Enio Chaves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Cirurgia Digestiva 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195465/
https://www.ncbi.nlm.nih.gov/pubmed/34133521
http://dx.doi.org/10.1590/0102-672020210001e1574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195465/
https://www.ncbi.nlm.nih.gov/pubmed/34133521
http://dx.doi.org/10.1590/0102-672020210001e1574

Ejemplares similares